113 related articles for article (PubMed ID: 27272838)
1. Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis.
Freier CP; Stiasny A; Kuhn C; Mayr D; Alexiou C; Janko C; Wiest I; Jeschke U; Kost B
Anticancer Res; 2016 Jun; 36(6):3131-7. PubMed ID: 27272838
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.
Stiasny A; Kuhn C; Mayr D; Alexiou C; Janko C; Wiest I; Jeschke U; Kost B
Anticancer Res; 2016 Jun; 36(6):3195-8. PubMed ID: 27272848
[TBL] [Abstract][Full Text] [Related]
3. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
[TBL] [Abstract][Full Text] [Related]
5. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
6. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
7. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
8. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
9. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.
Halle MK; Ojesina AI; Engerud H; Woie K; Tangen IL; Holst F; Høivik E; Kusonmano K; Haldorsen IS; Vintermyr OK; Trovik J; Bertelsen BI; Salvesen HB; Krakstad C
Am J Obstet Gynecol; 2017 Oct; 217(4):432.e1-432.e17. PubMed ID: 28599900
[TBL] [Abstract][Full Text] [Related]
11. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 product in patients with stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Breitenecker G
Anticancer Res; 1992; 12(6B):2241-2. PubMed ID: 1295470
[TBL] [Abstract][Full Text] [Related]
13. The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.
Stiasny A; Freier CP; Kuhn C; Schulze S; Mayr D; Alexiou C; Janko C; Wiest I; Dannecker C; Jeschke U; Kost BP
Oncol Lett; 2017 Oct; 14(4):4467-4476. PubMed ID: 29085443
[TBL] [Abstract][Full Text] [Related]
14. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 in patients with invasive cervical cancer stages IB to IIB.
Kainz C; Kohlberger P; Gitsch G; Sliutz G; Breitenecker G; Reinthaller A
Gynecol Oncol; 1995 May; 57(2):212-4. PubMed ID: 7729736
[TBL] [Abstract][Full Text] [Related]
16. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations in HPV-negative cervical carcinoma.
Park DJ; Wilczynski SP; Paquette RL; Miller CW; Koeffler HP
Oncogene; 1994 Jan; 9(1):205-10. PubMed ID: 8302581
[TBL] [Abstract][Full Text] [Related]
18. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
19. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix.
Uchiyama M; Iwasaka T; Matsuo N; Hachisuga T; Mori M; Sugimori H
Gynecol Oncol; 1997 Apr; 65(1):23-9. PubMed ID: 9103386
[TBL] [Abstract][Full Text] [Related]
20. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists.
Koivusalo R; Mialon A; Pitkänen H; Westermarck J; Hietanen S
Cancer Res; 2006 Dec; 66(24):11817-24. PubMed ID: 17178878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
